The IRB also categorized the technology as non-significant risk, which indicates the technology is fundamentally safe when used as directed.

Guided Therapeutics CEO and president Mark Faupel said they are excited to move ahead with the second product based on our patented light-based, disease detection platform.

"Receiving IRB approval, as well as being classified as ‘non-significant risk,’ are both very important achievements for advancing this product extension," Faupel said.

The new product for the detection of Barrett’s Esophagus, a precursor for esophageal cancer, is being co-developed with Konica Minolta Opto of Japan and is based on the company’s LightTouch non-invasive cervical cancer detection technology, which is undergoing the US Food and Drug Administration’s premarket approval process.